Gene editor Scribe starts second-half IPO spree with $129M listing

Benjamin Oakes, Scribe Therapeutics CEO July 23, 2026 10:01 PM EDT FinancingIPOs Gene ed­i­tor Scribe Ther­a­peu­tics starts sec­ond-half IPO spree with $129M list­ing Kyle LaHucik Biotech Correspondent A 9-year-old biotech co-found­ed by CRISPR pi­o­neer Jen­nifer Doud­na is kick­ing off a run of biotech IPOs set for this year’s sec­ond half. Scribe Ther­a­peu­tics … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER